| VEIEX | VEMAX | VEIEX / VEMAX | |
| Total Expense Ratio | 0.29 | 0.13 | 223% |
| Annual Report Gross Expense Ratio | 0.29 | 0.13 | 223% |
| Fund Existence | 32 years | 20 years | - |
| Gain YTD | 10.956 | 11.035 | 99% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 3000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 163B | 163B | 100% |
| Annual Yield % from dividends | 2.16 | 2.28 | 95% |
| Returns for 1 year | 21.91 | 22.07 | 99% |
| Returns for 3 years | 54.44 | 54.96 | 99% |
| Returns for 5 years | 24.35 | 24.98 | 97% |
| Returns for 10 years | 93.81 | 95.63 | 98% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| DFCEX | 34.35 | 0.23 | +0.67% |
| DFA Emerging Markets Core Equity 2 I | |||
| MUOAX | 35.26 | 0.03 | +0.09% |
| Morgan Stanley Instl US Core A | |||
| SEITX | 14.33 | N/A | N/A |
| SEI International Equity F (SIT) | |||
| TSLCX | 5.77 | N/A | N/A |
| Transamerica Small Cap Value C | |||
| FBTDX | 177.71 | -4.12 | -2.27% |
| Franklin Biotechnology Discovery C | |||